This multicenter, prospective, observational study aims to generate and analyze real-world data on the effectiveness and safety of Ruscus aculeatus L. treatment in patients with symptomatic chronic venous disease classified as CEAP C1-C6. Patients receiving Ruscus aculeatus L. as part of routine clinical practice will be followed for 90 days without any study-mandated intervention. Disease severity will be assessed using the revised Venous Clinical Severity Score (rVCSS), pain using the Visual Analog Scale (VAS), quality of life using the Chronic Venous Disease Quality of Life Questionnaire (CIVIQ-20), treatment adherence using the Visual Analog Scale for adherence (VAS-U), and safety through the collection of adverse events during the observation period.
Inclusion Criteria:
Exclusion Criteria:
nevzatkutay@gmail.com+90 532 427 18 20
Adults with symptomatic chronic venous disease (CEAP C1-C6) who are prescribed Ruscus aculeatus L. as part of routine clinical practice. Participants will be followed prospectively for approximately 90 days without any study-specific intervention. Clinical outcomes, treatment adherence, quality of life, and safety data will be collected during routine clinical visits at baseline, Day 30, and Day 90.
Ankara, Ankara, Turkey (Türkiye)
drcemalduzgun@gmail.com+90 532 477 43 31
Ankara, Ankara, Turkey (Türkiye)
Gaziantep, Gaziantep, Turkey (Türkiye)
Istanbul, Istanbul, Turkey (Türkiye)
Istanbul, Istanbul, Turkey (Türkiye)
Istanbul, Istanbul, Turkey (Türkiye)
Kahramanmaraş, Kahramanmaraş, Turkey (Türkiye)
Konya, Konya, Turkey (Türkiye)
Sivas, Sivas, Turkey (Türkiye)
evrenozcınar@gmail.com+90 532 622 96 72
kemal_esref@hotmail.com+90 555 300 53 35
ilkerince78@hotmail.com+90 505 589 43 39
dr-abdozer@hotmail.com+90 505 223 13 95
drgokhanarslan@gmail.com+90 532 736 80 19
tariktastekin@gmail.com+90 505 468 04 56
drmburakgulcan@gmail.com+90 533 960 73 69
drgokalpguzel@gmail.com+90 532 703 35 06
drseferkaya@hotmail.com+90 506 370 12 50
dradilpolat@gmail.com+90 532 230 24 75
drataym@gmail.com+90 542 723 61 11
helin_el@hotmail.com+90 505 655 07 26
unalaydin41@gmail.com+90 532 350 76 22
sinemyigit3@gmail.com+90 505 729 28 02
'muratbulent.rabus@sbu.edu.tr'+90 505 237 99 57
ketencilers@hotmail.com+90 532 622 75 60
hbolgi@yahoo.com+90 535 563 66 09
sahinboz@yahoo.com+90 533 236 24 42
emroguz@hotmail.com+90 535 896 90 35
drkirisci@yahoo.com+90 505 718 18 98
otanyeli@gmail.com+90 532 767 89 09
baris.akca@inonu.edu.tr+90 505 697 46 80
tpinaryusuf@gmail.com+90 538 367 95 84
nevzatkutay@gmail.com+90 532 427 18 20
Efficacy and Safety Evaluation of Ruscus Aculeatus L in Patients With Hemorrhoids
Effects of a Dietary Supplement Composed of Diosmin, Hesperidin, Bromelain, and Ruscus Aculeatus on the Quality of Life in Subjects With Lower Limb Disorders Possibly Prodromal to Chronic Venous Disease
Clinical Trial of Aesculus Hippocastanum and Associations Versus Diosmina and Hesperidina in Chronic Venous Insuficiency
Efficacy and Safety of the Use of Venocur Triplex® in Patients With Chronic Venous Insufficiency
Randomized, Placebo-crontrolled Clinical Trial Evaluating the Efficacy and Safety of Heparan Sulfate 120 mg Prolonged-Release Tablets Compared With Placebo in Patients With Chronic Venous Disease
Efficacy and Safety of Coumarin and Troxerutin in the Symptomatic Treatment of Chronic Venous Insufficiency
Efficacy and Tolerability of Venoactive Drugs in Patients With Chronic Venous Diseases C4a&b in Real Clinical Practice.
EXPLORATORY ASSESSMENT OF THE EFFECTS OF CYCLO 3 ® FORT (Ruscus Extract, Hesperidin Methyl Chalcone, Ascorbic Acid) OR MICRONISED PURIFIED FLAVONOID FRACTION ON VASCULAR PARAMETERS AND BIOMARKERS IN WOMEN SUFFERING FROM CHRONIC VENOUS DISEASE (CEAP C2 OR C3), OVER 8 WEEKS